- Home
- QNCX vs KNDI Comparison
QNCX vs KNDI Comparison
Compare QNCX & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- KNDI
- Stock Information
- Founded
- QNCX 2012
- KNDI 2002
- Country
- QNCX United States
- KNDI China
- Employees
- QNCX N/A
- KNDI N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- KNDI Auto Manufacturing
- Sector
- QNCX Health Care
- KNDI Consumer Discretionary
- Exchange
- QNCX Nasdaq
- KNDI Nasdaq
- Market Cap
- QNCX 100.4M
- KNDI 109.2M
- IPO Year
- QNCX 2019
- KNDI N/A
- Fundamental
- Price
- QNCX $1.98
- KNDI $1.23
- Analyst Decision
- QNCX Strong Buy
- KNDI
- Analyst Count
- QNCX 6
- KNDI 0
- Target Price
- QNCX $8.00
- KNDI N/A
- AVG Volume (30 Days)
- QNCX 431.7K
- KNDI 124.8K
- Earning Date
- QNCX 11-12-2025
- KNDI 11-17-2025
- Dividend Yield
- QNCX N/A
- KNDI N/A
- EPS Growth
- QNCX N/A
- KNDI N/A
- EPS
- QNCX N/A
- KNDI N/A
- Revenue
- QNCX N/A
- KNDI $104,035,613.00
- Revenue This Year
- QNCX N/A
- KNDI N/A
- Revenue Next Year
- QNCX N/A
- KNDI N/A
- P/E Ratio
- QNCX N/A
- KNDI N/A
- Revenue Growth
- QNCX N/A
- KNDI N/A
- 52 Week Low
- QNCX $0.71
- KNDI $0.89
- 52 Week High
- QNCX $2.45
- KNDI $1.81
- Technical
- Relative Strength Index (RSI)
- QNCX 62.46
- KNDI 44.61
- Support Level
- QNCX $1.82
- KNDI $1.20
- Resistance Level
- QNCX $2.01
- KNDI $1.35
- Average True Range (ATR)
- QNCX 0.16
- KNDI 0.06
- MACD
- QNCX 0.03
- KNDI 0.00
- Stochastic Oscillator
- QNCX 64.48
- KNDI 33.33
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.